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Abstract: Sunitinib malate is a novel oral multitargeted tyrosine kinase inhibitor with antitumor 
and antiangiogenic activities. Sunitinib was recently approved in ﬁ  rst-line treatment for patients 
with advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal 
stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate therapy. We 
report the very interesting results of the phase II trials after cytokin failure and of the randomized 
recent trial of sunitinib versus cytokin-based therapy in ﬁ  rst-line treatment for patients with 
metastatic RCC, as well as the promising results of the recent trials on patients with GIST after 
disease progression or intolerance to imatinib mesylate therapy. Oral sunitinib demonstrates a 
high level of efﬁ  cacy with acceptable tolerability with the 50 mg daily for 4 weeks followed by 
2 weeks off schedule; a continuous schedule could be of interest. Hypertension and asthenia are 
the most common side effects with sunitinib. Regardless of these encouraging results, studies 
investigating sunitinib in ﬁ  rst-line treatment (for patients with GIST), adjuvant and neoadjuvant 
settings are awaited, as well as trials using sunitinb in combination with chemotherapy or other 
targeted therapies. Clinical trials investigating sunitinib in other tumor types are ongoing.
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Introduction
Tyrosine kinase receptors, including platelet-derived growth factor receptors 
(PDGFRs), ﬁ  broblast growth factor receptors, and vascular endothelial growth 
factor receptors (VEGFRs) and their ligands, have been shown to play important 
roles in tumor growth and angiogenesis (Kerbel and Folkman 2002). Inhibition of 
VEGF signaling through the use of antibodies (Yang et al 2003; Ferrara et al 2004; 
Willett et al 2004) or VEGFR antagonists has demonstrated potent antitumor effects 
that might be used to circumvent resistance to classical anticancer agents (Shaheen 
et al 2001; Bergers et al 2003; Ahmad and Eisen 2004). Recently, the humanized 
anti-VEGF monoclonal bevacizumab antibody in combination with chemotherapy 
was associated with an increased survival in patients with advanced colon cancer 
(Hurwitz et al 2004).
Sunitinib (sunitinib malate; SU11248; SUTENTTM; Pﬁ  zer Inc, New York, NY) is 
a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic 
activities (Figure 1). Sunitinib has been identiﬁ  ed as a potent inhibitor of VEGFR-1, 
VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] 
receptor), PDGFRα, and PDGFRβ in both biochemical and cellular assays (Abrams, 
Lee, et al 2003; Mendel et al 2003). In vitro, sunitinib inhibited the growth of 
cell lines driven by VEGF, SCF, and PDGF and induced apoptosis of human 
umbilical vein endothelial cells (Mendel et al 2003). In vivo, sunitinib caused 
bone marrow depletion and effects in the pancreas in rats and monkeys, as well as Therapeutics and Clinical Risk Management 2007:3(2) 342
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adrenal toxicity in rat (microhemorrhage). In monkeys, a 
slight increase in arterial blood pressure and QT interval 
were reported at higher doses (Faivre et al 2006). Sunitinib 
exhibited dose- and time-dependent antitumor activity in mice, 
potently repressing the growth of a broad variety of human tumor 
xenografts (Abrams, Lee, et al 2003; Mendel et al 2003; Murray 
et al 2003; Morimoto et al 2004; Yee et al 2004). 
In vitro metabolism studies demonstrated that sunitinib 
was primarily metabolized by cytochrome CYP3A4, resulting 
in formation of a major, pharmacologically active N-desethyl 
metabolite, SU012662. This metabolite was shown to be 
equipotent to the parent compound in biochemical tyrosine 
kinase and cellular proliferation assays, acting toward 
VEGFR, PDGFR, and KIT (Baratte et al 2004). SU012662 
was the major plasma metabolite in mice, rats, and monkeys 
in vivo. SU012487 (an N-oxide metabolite) was the major 
metabolite in dog but was infrequently observed in human. 
Radiolabeled orally administrated sunitinib in preclinical 
species was primarily excreted in the feces. 
Pharmacokinetic and pharmacodynamic data from animal 
studies showed that target plasma concentrations of sunitinib 
plus SU012662 capable of inhibiting PDGFRβ and VEGFR-2 
phosphorylation were established in the range of 50 to 100 
ng/mL (Abrams, Lee, et al 2003; Abrams, Murray, et al 
2003; Mendel et al 2003; Murray et al 2003). Interestingly, 
those data were consistent with those observed in patients 
with acute myeloid leukemia in whom exposure to sunitinib 
led to a sustained inhibition of FLT3 phosphorylation in 
blast cells (O’Farrell et al 2003). Although initial studies 
were planned to provide continuous administration, the 
4-week-on, 2-week-off schedule was selected at the 
request of the Food and Drug Administration (FDA) 
and other global regulatory agencies to allow patients to 
recover from potential bone marrow and adrenal toxicity 
observed in animal models.
Sunitinib was recently approved for the treatment 
of advanced renal cell carcinoma (RCC) and for the 
treatment of gastrointestinal stromal tumors (GIST) after 
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Figure 1 Mechanism of action of sunitinib.
Abbreviations: FLT3, fetal liver tyrosine kinase receptor 3; KIT, stem cell factor receptor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor 
receptors; SCF stem-cell factor;   VEGF, vascular endothelial growth factor; VEGER, vascular endothelial growth factor receptors.Therapeutics and Clinical Risk Management 2007:3(2) 343
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disease progression or intolerance to imatinib mesylate 
therapy.
Sunitinib in the treatment of renal 
cell carcinoma
Renal cell carcinoma accounts for 3% of all adult cancer. 
Approximately one third of patients have distant metastases 
at presentation. Twenty ﬁ  ve percent to 50% of patients treated 
by nephrectomy for localized disease develop metastatic 
disease (Lam et al 2005). Approximately 50% of patients with 
metastases at presentation will survive less than one year and 
10% will survive for over 5 years (Motzer et al 2004). RCC 
is usually highly resistant to chemotherapy and radiotherapy. 
Standard first-line treatment for metastatic disease was 
immunotherapy with interferon-alpha and/or interleukin-2, 
achieving 6% to 20% response rates (Rohrmann et al 2005).
Renal cell carcinoma displays several histological 
types. The most common type of RCC is clear-cell RCC, 
accounting for 75% of cases (Motzer et al 1996). RCC are 
strongly associated with the von Hippel-Lindau (VHL) gene 
inactivation. RCC is a highly vascular tumor arising from 
epithelial elements of nephrons. An early event during the 
evolution of RCC is loss of function of the VHL gene (Latif 
et al 1993). In familial VHL-related RCC, the inheritance 
pattern is autosomal dominant (Latif et al 1993). The VHL 
gene is involved in the hypoxia-inducible pathway (Patel 
et al 2006). Speciﬁ  cally, the VHL gene product ubiquitinates 
transcriptional factor hypoxia-inducible factor (HIF)-1α 
(Kamura et al 2000). Physiologically, HIF-1 complex (a 
heterodimer composed of α and β subunits) regulates the 
expression of several genes in response to hypoxic stress 
(Wang and Semenza 1993). Human cells respond to hypoxic 
conditions through a series of pathways, many of which 
are mediated by HIF-1. In addition to regulation by VHL 
complex, HIF-1 activity is regulated by growth factor 
and cell adhesion pathways. HIF-1 binds to a variety of 
additional transcriptional cofactors, forming a preinitiation 
complex of proteins that ultimately activates transcription 
of hypoxia-inducible genes including VEGF leading to 
angiogenesis, epidermal growth factor receptor (EGFR) 
leading to cell growth, PDGF, and erythropoietin (Bardos 
and Aschcroft 2004). Phenotypically, RCC is a highly 
vascular tumor, with increased VEGF level, which growth 
could be stimulated by factors produced through the HIF-1 
pathway. Consequently, the inhibition of VEGF and PDGF 
signaling pathways may reverse, in part, the physiologic 
consequences of losing VHL protein function and may 
inhibit tumor progression.
In the early phase I trial by Faivre and colleagues (2006), 
twenty eight patients received sunitinib doses ranging from 
50 mg every other day to 150 mg daily. Dose-limiting 
toxicities reported at the maximum-tolerated doses ≥75 mg 
daily were reversible grade 3 fatigue, grade 3 hypertension, 
and grade 2 dermatitis. Therefore, the recommended dose 
was 50 mg daily for 4 weeks, followed by two weeks off per 
6 weeks. Interestingly, 3 patients with metastatic RCC had 
a sustained objective response, lasting 28, 36, and 54 weeks 
(Faivre et al 2006). 
This observation was the basis of the initiation of a 
large phase II trial including 63 patients with metastatic 
RCC who had failed cytokine-based therapy. Patients 
were treated with sunitinib monotherapy 50 mg daily for 
4 weeks, followed by 2 weeks off (Motzer, Michaelson, 
et al 2006). Fifty ﬁ  ve patients (87%) had clear cell histology. 
Only four patients (6%) had achieved objective response to 
prior cytokine-based therapy. Median duration of treatment 
with sunitinib was 9 months. Twenty ﬁ  ve of 63 patients 
(40%) achieved partial response and 17 patients (28%) 
had stable disease lasting more than 3 months (Table 1). 
Twenty four responders had clear cell histology and one had 
a papillary cell type. Responding lesions included sites of 
local recurrence and lymphatic, hepatic, pulmonary, bone, 
and adrenal metastases. Median time to progression was 8.7 
months and median overall survival was 16.4 months. The 
most commonly reported treatment-related grade 3 adverse 
events were fatigue (11%), nausea (3%), and diarrhea (3%) 
(Table 2). However, it is important to note that sunitinib 
may be considered as a maintenance treatment and that the 
grading system is designed mainly for chemotherapies that 
are usually not administered over prolonged periods. Thus 
the impact of fatigue, stomatitis, and other toxicities may be 
substantially underestimated. The most frequently reported 
grade 3 or 4 laboratory abnormalities were transient and 
asymptomatic elevated lipase (21%), neutropenia (13%), 
and anaemia (10%). Dose reductions were performed in 
22 patients (35%) from 50 mg to 37.5 mg daily, and the 
dose for two of these patients was further reduced to 25 mg 
daily. The most common reasons for dose reduction were 
asymptomatic hyperlipasemia or hyperamylasemia and 
fatigue. Circulating proteins that may represent potential 
biomarkers of angiogenic activity were measured. At the end 
of each cycle, VEGF levels were frequently increased, while 
sVEGFR-2 (a soluble variant of VEGFR-2) levels usually 
decreased. A trend was observed towards a larger proportional 
increase in VEGF levels and decrease in sVEGFR-2 levels 
in patients having objective response as compared with those Therapeutics and Clinical Risk Management 2007:3(2) 344
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with stable disease or progression (Deprimo et al 2005). 
The observed median time to progression in this study 
(8.7 months) compares favorably with the median times 
of 2.4 months for treatment in second line therapy at the 
Memorial Sloan-Kettering Cancer Center (Motzer et al 2004) 
and 2.5 months for treatment with placebo after cytokin 
failure in a phase II trial (Yang et al 2003).
A second phase II trial was conducted to conﬁ  rm the 
antitumor activity and safety observed in the ﬁ  rst phase 
II trial (Motzer, Rini, et al 2006). One hundred and six 
patients with metastatic clear cell RCC were included. All 
have had prior nephrectomy and failed ﬁ  rst-line cytokin-
based therapy. Median duration of treatment was 5 months. 
Thirty six patients (34%) had partial response (Table 1). 
Thirty patients (29%) had stable disease lasting more than 
3 months. The most commonly reported treatment-related 
grade 3 adverse events were fatigue (8%), hypertension 
(6%), stomatitis (5%), dermatitis (5%), and diarrhea 
(3%) (Table 2). The most frequently reported grade 3 or 
4 laboratory abnormalities were asymptomatic elevated 
lipase (15%), neutropenia (16%), thrombocytopenia (6%), 
and anaemia (6%). Dose reductions were performed in 
17 patients (16%) from 50 mg to 37.5 mg daily, and the 
dose for six of these patients was further reduced to 25 mg 
daily. The most common reasons for dose reduction were 
stomatitis and fatigue.
These outstanding results have led to a phase III trial 
comparing sunitinib with interferon-α as ﬁ  rst-line therapy in 
patients with metastatic RCC (Motzer, Hutson, et al 2006). 
Patients were randomized to receive sunitinib 50 mg daily 
for 4 weeks, with 2 weeks off (n = 375) or subcutaneous 
injection 9 MU three times weekly interferon-α (n = 375). 
Table 1 Efﬁ  cacy of sunitinib in trials with patients treated for renal cell carcinoma and GIST
 RCC  GIST
  Supportive (Motzer,   Pivotal  Phase III  Phase I/II  Phase III
  Michaelson, et al 2006)  (Motzer, Rini,   (Motzer, Hutson,   (Maki et al 2005)  (Demetri et al 2005)
  (n = 63)  et al 2006)  et al 2006)  (n = 97)  (n = 207)
    (n = 106)   (n = 374)
ORR  25 (40%)  46 (34%)  103 (31%)  8 (8%)  17 (8%)
SD  18 (28%)  24 (29%)  160 (48%)  36 (37%)  37 (18%)
TTP  8.7 months  8.3 months  11 months  7.8 months  6.3 months
OS  16.4 months  NR  NR  19.8 months  NR
Abbreviations: GIST, gastrointestinal stromal tumors; NR, not reached; ORR, overall response rate; OS, overall survival; RCC, renal cell carcinoma; SD, stable disease; TTP, 
time to progression. 
Table 2 Grade 3 or 4 toxicity of sunitinib in trials with patients treated for renal cell carcinoma and GIST
 RCC  GIST
  Supportive  Pivotal  Phase III  Phase I/II  Phase III
  (Motzer,   (Motzer, Rini,   (Motzer, Hutson,   (Maki et al 2005)  (Demetri 
  Michaelson, et al 2006)  et al 2006)  et al 2006)  (n = 97)  et al 2005)
  (n = 63)  (n = 106)   (n = 374)    (n = 207)
Nonhematological
Fatigue 11%  8%  7%  10%  7%
Diarrhea 3%    3%  5%  7%  4%
Nausea 3%    0%  3%  4%  1%
Dermatitis 2%    5%  5%  7%  5%
Stomatitis 2%    5%  1%  3%  NA
Asymptomatic 21%    15%  4%  13%  NA
lipase increase
Hypertension 2%    6%  8%  17%  4%
Hematological
Neutropenia 13%    13%  11%  NA  8%
Anemia 10%    6%  3%  NA  4%
Thrombocytopenia 0%    6%  8%  NA  5%
Abbreviations: GIST, gastrointestinal stromal tumor; NA, not available; RCC, renal cell carcinoma.Therapeutics and Clinical Risk Management 2007:3(2) 345
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Objective response rate in the sunitinib arm and in the 
interferon-α arm were respectively 31% and 6% (p < 0.000001) 
(Table 1). Median time to progression was signiﬁ  cantly longer 
in the sunitinib arm (11 vs 5 months) (p < 0.000001), as well 
as median overall survival (p = 0.02), although median overall 
survival has not yet been reached in either group. The most 
commonly reported treatment-related grade 3 or 4 adverse 
events were fatigue (7% vs 11% with interferon-α), diarrhea 
(5% vs 0% with interferon-α), and dermatitis (5% vs 0% 
with interferon-α) (Table 2). The most frequently reported 
grade 3 or 4 laboratory abnormalities were asymptomatic 
elevated lipase (4% vs 2% with interferon-α), neutropenia 
(11% vs 7% with interferon-α), and thrombocytopenia (8% 
vs 0% with interferon-α). Thirty patients (8%) withdrew 
from the study due to adverse event on sunitinib arm versus 
49 patients (13%) on interferon-α arm. This study is the ﬁ  rst 
phase III trial demonstrating a clearly clinical superiority 
over immunotherapy, with a favorable toxicity proﬁ  le. Thus, 
sunitinib becomes the new standard in ﬁ  rst-line treatment in 
patients with metastatic RCC.
Before sunitinib, other targeted therapies had been 
studied in metastatic RCC. Sorafenib, an oral multitargeted 
tyrosine kinase inhibitor, had also been studied in metastatic 
RCC. Sorafenib was identiﬁ  ed as a potent inhibitor of 
VEGFR-2, VEGFR-3, FLT3, PDGFRβ, and KIT. Results 
with sorafenib are consistent with sunitinib results (Escudier 
et al 2005; Ratain et al 2005). Interestingly, the partial 
response rate induced by sorafenib is slightly lower to 
that of sunitinib, and the stable disease rate is similar. 
The relatively lower partial response rate associated 
with sorafenib may be related to the differential binding 
afﬁ  nity of tyrosine kinase receptors including VEGFR-2 
and PDGFRβ that is thought to be weaker for sorafenib 
as compared with that of sunitinib (Fabian et al 2005). So 
far, single agent clinical trials in RCC patients with either 
monoclonal antibodies or single molecules that block 
EGFR tyrosine kinase activity (eg, with erlotinib) have 
been disappointing (Yang et al 2003). 
Sunitinib in the treatment of GIST
Approximately 85% of patients with GIST display activating 
mutations of KIT (Heinrich et al 2003; Corless et al 2004). 
Another 5% to 7% patients have activating mutations of 
PDGFRα (Heinrich et al 2003; Coreless et al 2005). Current 
standard of care for unresectable or malignant GIST is imatinib 
mesylate, a KIT and PDGFRα inhibitor (Blanke and Corless 
2005). Approximately 12% to 14% of patients have primary 
resistance to imatinib (Demetri et al 2002; Van Glabbeke 
et al 2005). Furthermore, more than 40% of patients who 
initially responded to imatinib develop secondary imatinib 
resistance after a median of 18 to 26 months of treatment 
(Verweij et al 2004). Sunitinib had previously shown 
promising results in one patient with GIST failing prior 
therapy with imatinib mesylate in the phase I trial (Faivre 
et al 2006).
An open label multicenter phase I/II study of sunitinib 
in 97 patients with GIST showing progression or 
intolerance under imatinib mesylate therapy conﬁ  rmed the 
recommended dose for sunitinib as 50 mg daily during 4 
weeks with 2 weeks off (Maki et al 2005). Median time to 
progression was 7.8 months, and median overall survival 
19.8 months. Thirty two patients (45%) had partial response 
or stable disease lasting more than 6 months (Table 1). The 
most commonly reported treatment-related grade 3 or 4 
adverse events were fatigue (10%), hypertension (17%), 
and asymptomatic lipase increase (13%) (Table 2). Tumor 
determination of KIT and PDGFRα mutations identiﬁ  ed 
that median time to progression, as well as median 
overall survival, were signiﬁ  cantly longer in patients with 
primary KIT exon 9 mutations or wild type versus primary 
KIT exon 11 mutations (14.3 and 13.8 vs 5.1 months, 
respectively).
A double-bind, placebo-controlled, multicenter, 
randomized phase III trial conﬁ  rmed the efﬁ  cacy and safety 
of sunitinib as second line therapy in 312 patients with 
GIST showing disease progression or intolerance under 
imatinib mesylate therapy (Demetri et al 2005). Patients 
were randomized in a 2:1 ratio to receive sunitinib 50 mg 
daily for 4 weeks, with 2 weeks off (n = 207) or placebo 
(n = 105). Objective response rate in the sunitinib arm and 
in the placebo arm were 8% and 0%, respectively (Table 1). 
Median time to progression was signiﬁ  cantly longer in the 
sunitinib arm (6.3 vs 1.5 months), as well as median overall 
survival (hazard ratio, 0.491), although median overall 
survival has not yet been reached in either group. Fifty 
nine patients in the placebo group crossed over to sunitinib 
therapy due to disease progression. Ten percent had 
subsequent partial responses, suggesting that the optimal 
therapeutic effect of sunitinib may be observed when it was 
administered in the early disease phase. The most commonly 
reported treatment-related grade 3 or 4 adverse events were 
fatigue (7% vs 3% with placebo) and dermatitis (5% vs 0% 
with placebo) (Table 2). The most frequently reported grade 
3 or 4 laboratory abnormalities were neutropenia (8% vs 
0% with placebo) and thrombocytopenia (5% vs 0% with 
placebo).Therapeutics and Clinical Risk Management 2007:3(2) 346
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Conclusions and future directions
Sunitinib has demonstrated a high level of efﬁ  cacy with 
acceptable tolerability in both metastatic RCC and in GIST 
after disease progression or intolerance to imatinib mesylate 
therapy, leading to the recent ﬁ  rst joint FDA approval for use 
in these 2 indications. Sunitinib also shows promising activity 
in other tumor such as breast cancer (Miller et al 2005), 
colorectal cancer (Lenz et al 2006), advanced non-small 
cell lung cancer (Socinski et al 2006), and neuroendocrine 
tumors (Kulke et al 2005). Phase II trials in patients with 
hepatocarcinoma and other solid tumors are ongoing. 
The actual requested schedule for sunitinib administration 
is 6-week cycles of 4 weeks on treatment followed by 2 weeks 
off. The hypothesis that a potential tumor reactivation of 
tumor cells during the off-treatment period could occur has 
led to study continuous schedules. Phase II trials in patients 
with cytokine refractory metastatic RCC (De Mulder et al 
2006), and imatinib-resistant GIST (George et al 2006) were 
performed in a continuous dose of 37.5 mg daily of sunitinib, 
and demonstrated that this continuous schedule is well 
tolerated. In this case, only few patients required treatment 
breaks or dose reduction.
Sunitinib has shown very promising results when 
used alone. Studies including other compounds with 
antiangiogenic properties such as bevacizumab have 
shown that the best efﬁ  cacy was observed when combined 
to “classical” chemotherapy (Hurwitz et al 2004). Thus, 
combinations of sunitinib with these types of agents are 
ongoing. Another way to improve the antitumor activity 
could be to block different signaling pathways to overlap 
potential resistances to sunitinib. The combination of 
sunitinib and geﬁ  tinib, an EGFR inhibitor, has been tested in 
a phase I trial in patients with metastatic RCC (Ronnen et al 
2006). The combination was well tolerated. The efﬁ  cacy is 
being assessed in a phase II trial. Moreover, temsirolimus, a 
speciﬁ  c inhibitor of mammalian target of rapamycin (mTOR) 
that regulates cell growth and angiogenesis through the PI3K/
AKT/mTOR pathway, has shown a very promising activity 
in ﬁ  rst-line treatment compared with cytokin-based therapy 
in metastatic RCC (Hudes et al 2006). The combination 
of sunitinib with temsirolimus could be of great interest, 
particularly in RCC.
The results of sunitinib in GIST patients indicate that 
sunitinib has a greater efﬁ  cacy in patients with primary 
KIT exon 9 mutations or wild type status than in those with 
primary KIT exon 11 mutations, suggesting that patients with 
KIT exon 9 mutations or wild type should receive sunitinib 
as ﬁ  rst-line treatment.
Hypertension and asthenia are the most common side effects 
reported at the recommended doses of sunitinib. They have been 
observed with several other antiangiogenic therapies (Yang et al 
2003; Ahmad and Eisen 2004; Willett et al 2004).
The majority of patients treated with sunitinib for 
metastatic RCC or GIST have stable disease with prolonged 
progression free survival, albeit response rates are sometimes 
low. Responding patients generally exhibit evidence of early 
tumor necrosis during the ﬁ  rst treatment cycles. The size 
of the lesions is often stable. Most of the time, although 
central necrosis appears on computed tomography (CT) scan, 
contrast enhancement peripheral area persists, suggesting that 
viable tumor cells are not destroyed with sunitinib. When 
progression occurs, it is usually observed from the peripheral 
area of the tumor. These observations rise the question of the 
relevance of the RECIST criteria for the assessment of response 
to sunitinib, and in general for targeted therapies. Previous 
clinical studies suggest that [18F]ﬂ  uorodeoxyglucose positron-
emission tomography could be useful for the assessment of 
response in detecting early inhibition of intratumoral metabolic 
activity (Toner et al 2003). Measurement of CT scan density 
seems also to be of interest.
Considering the great efﬁ  cacy of sunitinib in advanced 
RCC and GIST, trials to test the efﬁ  cacy of sunitinib in the 
adjuvant or neoadjuvant setting for patients with high risk 
of recurrence tumors are greatly awaited.
Sunitinib belongs to a new class of multitargeted 
compounds that have demonstrated a high level of efﬁ  cacy 
in metastatic RCC and GIST after disease progression or 
intolerance to imatinib mesylate therapy. Sunitinib malate has 
now been recognized as the standard treatment in ﬁ  rst-line for 
patients with metastatic RCC. Sunitinib shows also promising 
activity in other types of cancer. Studies in adjuvant and 
neoadjuvant settings are awaited, as well as trials exploring 
the combination of sunitinb with chemotherapy or other 
targeted therapies.
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